Use of the CHA 2 DS 2 -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation
出版年份 2012 全文链接
标题
Use of the CHA
2
DS
2
-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation
作者
关键词
-
出版物
CIRCULATION
Volume 126, Issue 7, Pages 860-865
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2012-08-14
DOI
10.1161/circulationaha.111.060061
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antithrombotic Therapy for Atrial Fibrillation
- (2012) John J. You et al. CHEST
- Reliable Identification of “Truly Low” Thromboembolic Risk in Patients Initially Diagnosed With “Lone” Atrial Fibrillation
- (2012) Tatjana S. Potpara et al. Circulation-Arrhythmia and Electrophysiology
- Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study
- (2012) Leif Friberg et al. EUROPEAN HEART JOURNAL
- Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED Bleeding Risk–Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation
- (2012) Stavros Apostolakis et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study
- (2012) Christian Torp-Pedersen et al. THROMBOSIS AND HAEMOSTASIS
- Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review
- (2011) Dan Pugh et al. AGE AND AGEING
- A New Risk Scheme to Predict Warfarin-Associated Hemorrhage
- (2011) Margaret C. Fang et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The role of aspirin for stroke prevention in atrial fibrillation
- (2011) Gregory Y. H. Lip Nature Reviews Cardiology
- Bleeding risk assessment and management in atrial fibrillation patients
- (2011) Laurent Fauchier et al. THROMBOSIS AND HAEMOSTASIS
- Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study
- (2011) Gregory Lip et al. THROMBOSIS AND HAEMOSTASIS
- Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke
- (2011) Emma Wallace et al. THROMBOSIS AND HAEMOSTASIS
- Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study
- (2011) Amitava Banerjee et al. THROMBOSIS AND HAEMOSTASIS
- Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review
- (2010) Isla M. Ogilvie et al. AMERICAN JOURNAL OF MEDICINE
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
- (2010) Ron Pisters et al. CHEST
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
- (2010) et al. EUROPEAN HEART JOURNAL
- Age as a Risk Factor for Stroke in Atrial Fibrillation Patients
- (2010) Ricarda Marinigh et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?
- (2010) John W. Eikelboom et al. THROMBOSIS AND HAEMOSTASIS
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
- (2009) Gregory Y.H. Lip et al. CHEST
- Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation
- (2009) Carl van Walraven et al. STROKE
- Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
- (2008) STROKE
- Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated
- (2008) David J. Gladstone et al. STROKE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started